Sanofi Genzyme News |

Featured Press Releases

January 9, 2019
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP).aTTP is a rare, life-threatening autoimmune blood disorder characterized by extensive clot formation in small blood...
November 29, 2018
Sanofi builds focus on rare blood disorders and cancers
Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research as scientists look for new treatments for serious and life-threatening conditions.
November 6, 2018
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical...
October 19, 2018
FDA approves asthma indication for Dupixent® (dupilumab)
The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

“The PAL Awards put our mission into action,” said Sebastien Martel, Global Head of Rare Diseases. “The organizatio… https://t.co/J2AWlw6l93-1 day 2 hours ago

.@NEJM publishes results from pivotal phase 3 trial of an investigational therapy for acquired thrombotic thrombocy… https://t.co/J2C8jodkBZ-1 week 17 hours ago

We know there’s more to our #Sanofi team members than the work they do. That’s why we provide work-life benefits to… https://t.co/H300h54msl-3 weeks 23 hours ago

As a way to #giveback during the holidays, a group of our employees enjoyed spending the day at @c2cboston! https://t.co/2FstvnY2ZN-4 weeks 1 day ago

This week, EVP, Bill Sibold, visited our Waterford, Ireland Industrial Affairs site where he met with… https://t.co/7lGJ6AF46Z-4 weeks 6 days ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media